Fortinet launches Singapore NDR cloud PoP to strengthen threat detection across ASEAN
YesAsia Holdings Advances Dual-Engine Strategy with First YesStyle Concept Store in the US
Haven Safety AI Announces Product Availability in Australia, Marking First International Expansion
U.S. Polo Assn. Returns to Downtown London as Official Apparel and Jersey Partner of Chestertons Polo in the Park
Doubleview Reports Assays from Drill Holes H102-H108, Extends Hat Mineralization Approximately 150m East and Identifies Gold-Enriched Intervals
Novel Technology Identified Genes that Promote T Cell Exhaustion, and which are Unique from PD-1/PD-L1…
ERAS-601, a potential best-in-class SHP2 inhibitor, blocks oncogenic signal transduction to delay onset of therapeutic…
ERAS-601, a potential best-in-class SHP2 inhibitor, blocks oncogenic signal transduction to delay onset of therapeutic…
ImCheck Achieves the Primary Objectives of Phase I of the EVICTION-2 Trial of ICT01 in…
ImCheck Achieves the Primary Objectives of Phase I of the EVICTION-2 Trial of ICT01 in…
Data presented at AACR Annual Meeting support IMM-1-104’s potential to address a broad population of…
Data presented at AACR Annual Meeting support IMM-1-104’s potential to address a broad population of…
Preclinical data suggests that sudocetaxel zendusortide can induce immune cell infiltration in “cold” tumors and…
Preclinical data suggests that sudocetaxel zendusortide can induce immune cell infiltration in “cold” tumors and…
Data demonstrated D-4559 switches tumor associated macrophages from an M2 to M1 pro-inflammatory phenotype leading…
Data demonstrated D-4559 switches tumor associated macrophages from an M2 to M1 pro-inflammatory phenotype leading…
– 100% accuracy predicting clinical responders with Notable’s PPMP with enhanced machine learning – – Fourth clinical…
– 100% accuracy predicting clinical responders with Notable’s PPMP with enhanced machine learning – – Fourth clinical…
APN401 induced prolonged stable disease in two heavily pre-treated patients, using invIOs’s proprietary rapid cell-processing…
APN401 induced prolonged stable disease in two heavily pre-treated patients, using invIOs’s proprietary rapid cell-processing…
NEW YORK, April 18, 2023 (GLOBE NEWSWIRE) — Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”)…
NEW YORK, April 18, 2023 (GLOBE NEWSWIRE) — Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”)…
ORLANDO, Fla., April 18, 2023 (GLOBE NEWSWIRE) — Elevar Therapeutics, Inc., a fully integrated biopharmaceutical…
ORLANDO, Fla., April 18, 2023 (GLOBE NEWSWIRE) — Elevar Therapeutics, Inc., a fully integrated biopharmaceutical…
Qualigen Therapeutics, Inc. Abstract #4981 Qualigen Therapeutics, Inc. Abstract #6240 CARLSBAD, Calif., April 18, 2023…